TICKERNERD
Menu
FULCFULCHealthcare · Biotechnology

FULC Stock Forecast: Fulcrum Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$3.75
+2.18% on the day

The 5 Wall Street analysts covering Fulcrum Therapeutics, Inc. hold a median 12-month price target of $4 — +6.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$281.5M
Ticker Nerd rank
38 / 100
Median analyst target
$4.00
Analysts covering
5
Revenue$0.0
Operating income−$19.9M
Net income−$26.2M
Free cash flow−$16.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.9%
1M
−1.8%
YTD
−66.8%
1Y
−61.1%
From 52W high
−74.3%
From 52W low
+19.4%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FULC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fulcrum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
66
Size
62
Accruals
59
Growth
58
Volatility
50
Issuance
48
Revisions
48
Momentum
17
Value
17

Quality (66): The business earns solid, repeatable profits on what it owns.

Value (17): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FULC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FULC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26FULCHigh $4.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
0 Buy4 Hold1 Sell
Low $3.00Median $4.00High $4.00

The green dot is the last close — the median target sits +6.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
3 June 2026JP MorganDowngradeUnderweight—
2 June 2026HC Wainwright & Co.DowngradeNeutral$25 → $3.00
2 June 2026Leerink PartnersDowngradeMarket Perform$24 → $4.00
2 June 2026Piper SandlerDowngradeUnderweight$23 → $3.00
2 June 2026StifelDowngradeHold$25 → $3.00
2 June 2026Truist SecuritiesDowngradeHold$17 → $4.00
12 Jan 2026JP MorganInitiatesOverweight—
11 Dec 2025Truist SecuritiesMaintainsBuy—
9 Dec 2025B of A SecuritiesMaintainsUnderperform—
8 Dec 2025Cantor FitzgeraldMaintainsOverweight—
8 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025Piper SandlerReiteratesOverweight—
8 Dec 2025RBC CapitalMaintainsSector Perform—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
24 Nov 2025Truist SecuritiesInitiatesBuy—
30 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025RBC CapitalMaintainsSector Perform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
30 July 2025RBC CapitalMaintainsSector Perform—
29 July 2025HC Wainwright & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FULC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FULC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Fulcrum Therapeutics, Inc. returned −61.1% against +16.2% for the S&P 500, dividends included.

FULC vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26FULCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FULC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Fulcrum Therapeutics, Inc. (FULC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.1×

Cheaper than 88% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
0.4×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.4%

Higher than 26% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fulcrum Therapeutics, Inc. (FULC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fulcrum Therapeutics, Inc. has a market value of $281.5M and an enterprise value of −$32.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$85.0M.

  • Diluted earnings per share, trailing twelve months: $−1.21.

  • Free cash flow in the twelve months to 30 June 2026: −$66.1M.

  • Shares outstanding: 76.3M.

  • Trailing P/E: −3.1×; forward P/E: −6.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Fulcrum Therapeutics, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

FULC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FULCFulcrum Therapeutics, Inc.$281.5M
38
EYPTEyePoint, Inc.$286.4M
11
LRMRLarimar Therapeutics, Inc.$285.1M
29
RCKTRocket Pharmaceuticals, Inc.$284.6M
58
ABEOAbeona Therapeutics, Inc.$283.0M
40
BNTCBenitec Biopharma, Inc.$294.5M
39
XFORX4 Pharmaceuticals, Inc.$276.6M
58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fulcrum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FULC news & analysis

Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights

Newsfile Corp · 6 Oct 2026negative

Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations involving Fulcrum Therapeutics. The firm invited investors who suffered losses, or people with relevant information, to contact it.

Why it matters — FULC investors may follow the investigation and any information about potential securities violations involving the company.

Kaplan Fox Investor Alert: Fulcrum Therapeutics, Inc. (FULC) Investigated for Possible Securities Law Violations

Newsfile Corp · 2 Oct 2026negative

Law firm Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is seeking investors who have suffered losses or who have information that could assist in the investigation.

Why it matters — A securities-law investigation into the company could signal concerns about its disclosures or conduct, and may affect investor confidence in FULC.

Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations

Newsfile Corp · 30 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced that it is investigating potential securities law violations against Fulcrum Therapeutics, Inc. and its board. The firm is seeking to hear from Fulcrum investors who have suffered losses or who have information relevant to the investigation.

Why it matters — A securities investigation into the company and its board introduces legal and regulatory uncertainty that Fulcrum Therapeutics watchers would want to monitor.

Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Pending Securities Investigation

Newsfile Corp · 28 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). The firm is seeking contact from Fulcrum Therapeutics investors who have suffered losses or who may have information relevant to the investigation.

Why it matters — The launch of a securities investigation introduces legal and regulatory uncertainty for Fulcrum Therapeutics investors.

Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (FULC) Investors: The Firm is Investigating Possible Securities Law Violations

Newsfile Corp · 24 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities law violations involving Fulcrum Therapeutics, Inc. The firm is seeking information from investors who have suffered losses or who may have knowledge relevant to the investigation.

Why it matters — A securities investigation can signal regulatory or legal scrutiny of the company, which FULC watchers may want to monitor closely.

FAQ

Frequently asked questions about FULC stock

What is the FULC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Fulcrum Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FULC stock a buy right now?

Of the 5 analysts covering Fulcrum Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Fulcrum Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FULC?

As at 8 Oct 2026, Fulcrum Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (66 of 100).

Will FULC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +6.7% from the last close, and Ticker Nerd's factor model ranks Fulcrum Therapeutics, Inc. 38 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FULC stock forecast for 2030?

No analyst covering Fulcrum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FULC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has FULC stock performed over the past year?

Fulcrum Therapeutics, Inc. returned -61.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fulcrum Therapeutics, Inc. do?

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases.

What is the latest news on FULC?

The most recent item we track (Newsfile Corp, 6 Oct 2026): "Kaplan Fox Encourages Fulcrum Therapeutics, Inc. (FULC) Investors Who Suffered Losses to Learn About Their Legal Rights". Kaplan Fox & Kilsheimer LLP said it is investigating potential securities violations involving Fulcrum Therapeutics. The firm invited investors who suffered losses, or people with relevant information, to contact it.

Company

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin expression and is being studied for sickle cell disease. Fulcrum Therapeutics also advances research programs in other serious hematologic and rare disorders, including beta-thalassemia and inherited aplastic anemias, while maintaining a broader focus on areas of high unmet medical need. Based in Cambridge, Massachusetts, Fulcrum Therapeutics plays a specialized role in the biotechnology market as a developer of precision medicines for challenging diseases with limited treatment options.

CEO Mr. Alexander C. Sapir · 9 employees · United States · https://www.fulcrumtx.com